MCID: FXF002
MIFTS: 36

Fox-Fordyce Disease malady

Categories: Rare diseases, Skin diseases

Aliases & Classifications for Fox-Fordyce Disease

Aliases & Descriptions for Fox-Fordyce Disease:

Name: Fox-Fordyce Disease 12 50 42 14
Fox Fordyce Disease 12 69
Fox-Fordyce Syndrome 50
Miliaria, Apocrine 50
Apocrine Miliaria 50

Classifications:



External Ids:

Disease Ontology 12 DOID:1381
ICD10 33 L75.2
ICD9CM 35 705.82
MeSH 42 D005588
NCIt 47 C84716
SNOMED-CT 64 254682006 65038009
UMLS 69 C0016632

Summaries for Fox-Fordyce Disease

NIH Rare Diseases : 50 fox-fordyce disease is a chronic skin disease most common in women aged 13-35 years. it is characterized by the development of intense itching in the underarm area, the pubic area, and around the nipple of the breast as a result of perspiration which becomes trapped in the sweat gland and surrounding areas. the cause is unknown, but heat, humidity, and stress may play a role. treatment may include the use of retinoids, antibiotics, and immunosuppressants. last updated: 8/3/2016

MalaCards based summary : Fox-Fordyce Disease, also known as fox fordyce disease, is related to xanthomatosis and rhabdoid cancer. An important gene associated with Fox-Fordyce Disease is OSMR (Oncostatin M Receptor), and among its related pathways/superpathways is Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Dopamine and Memantine have been mentioned in the context of this disorder. Affiliated tissues include skin and breast.

Wikipedia : 71 Fox–Fordyce disease, or apocrine miliaria, is a chronic blockage of the sweat gland ducts with a... more...

Related Diseases for Fox-Fordyce Disease

Diseases related to Fox-Fordyce Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 50)
id Related Disease Score Top Affiliating Genes
1 xanthomatosis 10.3
2 rhabdoid cancer 10.2 KIT OSMR
3 speech disorder 10.1 CEACAM5 KIT
4 vulva basal cell carcinoma 10.1 CEACAM5 KIT
5 precursor t-lymphoblastic lymphoma/leukemia 10.1 CEACAM5 KIT
6 hidradenitis 10.1
7 miliaria 10.1
8 sphenoid sinus squamous cell carcinoma 10.1 CEACAM5 KIT
9 wells syndrome 10.1 CEACAM5 KIT
10 cranial nerve disease 10.1 CEACAM5 KIT
11 bartholin's gland adenoid cystic carcinoma 10.1 CEACAM5 PIP
12 subendocardial myocardial infarction 10.1 CEACAM5 KIT
13 parietal lobe neoplasm 10.1 CEACAM5 PIP
14 tubular adenocarcinoma 10.1 CEACAM5 PIP
15 vulvar angiokeratoma 10.1 CEACAM5 PIP
16 vulva squamous cell carcinoma 10.1 CEACAM5 PIP
17 myotonia congenita 10.1 CEACAM5 PIP
18 laryngeal neuroendocrine tumor 10.0 KIT PIP
19 cellulitis 10.0 CD68 OSMR
20 advanced sleep phase syndrome 10.0 CEACAM5 KIT
21 neutropenia, severe congenital, 5, autosomal recessive 10.0 CEACAM5 OSMR
22 endocrine organ benign neoplasm 10.0 CEACAM5 KIT
23 myotonic disease 10.0 CEACAM5 PIP
24 chondroid lipoma 10.0 CD68 KIT
25 freemartinism 10.0 CD68 KIT
26 ovarian endometrioid cystadenofibroma 10.0 CD68 CEACAM5
27 choriocarcinoma of ovary 10.0 CD68 KIT
28 pigmented villonodular synovitis 10.0 CD68 CEACAM5
29 premature menopause 10.0 CD68 MRAP
30 alpha chain disease 10.0 KIT PIP
31 cerebral arterial disease 10.0 CD68 KIT
32 endodermal sinus tumor 10.0 CD68 KIT
33 lipid-rich carcinoma 10.0 CD68 MRAP
34 pinta disease 10.0 CD68 CEACAM5
35 ovarian mucinous malignant adenofibroma 10.0 CD68 KIT
36 muscular dystrophy-dystroglycanopathy , type a, 10 10.0 CEACAM5 OSMR
37 hidradenitis suppurativa 10.0
38 turner syndrome 10.0
39 syringoma 10.0
40 partial of retinal vein occlusion 10.0 CD68 CEACAM5
41 mitochondrial dna depletion syndrome 5 10.0 CEACAM5 KIT
42 proctitis 10.0 CEACAM5 KIT
43 bulbar polio 9.9 CD68 CEACAM5
44 jewett-marshall bladder cancer 9.9 CD68 CEACAM5
45 nelson syndrome 9.9 CD68 KIT
46 retinal disease 9.9 CD68 PIP
47 gestational choriocarcinoma 9.9 CD68 KIT
48 malignant pleural solitary fibrous tumor 9.8 CEACAM5 KIT
49 squamous blepharitis 9.8 CD68 CEACAM5 PIP
50 hypoglossal nerve disease 9.2 CD68 CEACAM5 KIT MRAP OSMR PIP

Graphical network of the top 20 diseases related to Fox-Fordyce Disease:



Diseases related to Fox-Fordyce Disease

Symptoms & Phenotypes for Fox-Fordyce Disease

Drugs & Therapeutics for Fox-Fordyce Disease

Drugs for Fox-Fordyce Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 721)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
2
Memantine Approved, Investigational Phase 4,Phase 3 19982-08-2 4054
3
Treprostinil Approved, Investigational Phase 4 81846-19-7 54786 6918140
4
Acetylcholine Approved Phase 4 51-84-3 187
5
Epoprostenol Approved Phase 4 61849-14-7, 35121-78-9 5280427 5282411
6
Iloprost Approved, Investigational Phase 4,Phase 1,Phase 2 78919-13-8 6443959
7
Tadalafil Approved, Investigational Phase 4,Phase 3 171596-29-5 110635
8
Pramipexole Approved, Investigational Phase 4,Phase 2 104632-26-0 59868 119570
9
Zoledronic acid Approved Phase 4,Phase 3,Phase 2 118072-93-8 68740
10
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
11
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
12
Nicotine Approved Phase 4,Phase 2 54-11-5 942 89594
13
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
14
Insulin Glargine Approved Phase 4 160337-95-1
15
Zinc Approved Phase 4,Phase 3 7440-66-6 32051 23994
16
Ethanol Approved Phase 4,Phase 2,Phase 1 64-17-5 702
17
Amantadine Approved Phase 4,Phase 2 768-94-5 2130
18
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
19
Ropinirole Approved, Investigational Phase 4,Phase 2 91374-20-8, 91374-21-9 5095 497540
20
Methylphenidate Approved, Investigational Phase 4,Phase 3 113-45-1 4158
21
Phentolamine Approved Phase 4 50-60-2 5775
22
Fesoterodine Approved Phase 4 286930-02-7, 286930-03-8 6918558
23
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
24
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
25
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
26
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
27
Ibuprofen Approved Phase 4 15687-27-1 3672
28
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
30
Caffeine Approved, Nutraceutical Phase 4 58-08-2 2519
31 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2
34 Excitatory Amino Acids Phase 4,Phase 3,Phase 2
35 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
38 abobotulinumtoxinA Phase 4
39 Botulinum Toxins Phase 4
40 Botulinum Toxins, Type A Phase 4
41 Cholinergic Agents Phase 4,Phase 3,Phase 2
42 incobotulinumtoxinA Phase 4
43 onabotulinumtoxinA Phase 4
44 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3
45 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2
46 Tezosentan Phase 4
47 Vardenafil Dihydrochloride Phase 4
48 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 1334)
id Name Status NCT ID Phase
1 Memantine for Agitation in Dementia Unknown status NCT00371059 Phase 4
2 Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain Unknown status NCT01615627 Phase 4
3 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4
4 Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids. Unknown status NCT00705588 Phase 4
5 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
6 Merck IISP Stewardship Grant for Antibiotic Best Practices Completed NCT01573195 Phase 4
7 The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes Completed NCT00353834 Phase 4
8 Effects of White Wine vs. Tea Intake During and an Alcoholic Digestive Following a High Fat, High Calorie Cheese Fondue Meal on Gastric Emptying and Abdominal Symptoms in Healthy Volunteers Completed NCT00943696 Phase 4
9 Validation of Dyskinesia Rating Scales Completed NCT01071395 Phase 4
10 Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4
11 Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease Completed NCT00526630 Phase 4
12 Spy II Clinical Registry Completed NCT00751998 Phase 4
13 A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE) Completed NCT00096928 Phase 4
14 A Multiple Myeloma Trial in Patients With Bone Metastases Completed NCT00104104 Phase 4
15 A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine. Completed NCT01302054 Phase 4
16 Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging Completed NCT01221272 Phase 4
17 A Study to Determine if Caffeine Accelerates Emergence From Anesthesia Recruiting NCT02567968 Phase 4
18 Kunxian for the Treatment of Rheumatoid Arthritis Recruiting NCT02764515 Phase 4
19 Fentanyl Patch Pharmacokinetics in Healthy Adults Recruiting NCT02531971 Phase 4
20 Transdermal Patch CVD 2000: The Effect of Heat on Fentanyl Release From Fentanyl Patches in Healthy Adults Recruiting NCT02486016 Phase 4
21 Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF) Recruiting NCT02827500 Phase 4
22 Atrial Fibrillation Progression Trial Recruiting NCT01570361 Phase 4
23 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Active, not recruiting NCT02151149 Phase 4
24 Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator Active, not recruiting NCT01742299 Phase 4
25 Safety and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients Not yet recruiting NCT02583399 Phase 4
26 An Adequate Cost Effective Follow Up Protocol For Bone & Soft Tissue Sarcomas - A Prospective Randomized Trial Unknown status NCT00384735 Phase 3
27 Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy Unknown status NCT00516464 Phase 3
28 Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients Unknown status NCT01333358 Phase 3
29 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
30 Treating H. Pylori in Parkinson's Patients With Motor Fluctuations Unknown status NCT00664209 Phase 3
31 Boost Use in Breast Conservation Radiotherapy Unknown status NCT00138814 Phase 3
32 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
33 Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors Unknown status NCT00566852 Phase 3
34 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Unknown status NCT00954174 Phase 3
35 Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) Unknown status NCT00117572 Phase 3
36 Vaccine Therapy for Patients With Stage III Melanoma Unknown status NCT00052130 Phase 3
37 A Multi-Centered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 (Zuragen) Solution, and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chronic Central Venous Catheters for Dialysis Unknown status NCT00628680 Phase 3
38 Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization Unknown status NCT00438867 Phase 3
39 Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation Unknown status NCT00691470 Phase 2, Phase 3
40 Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer Unknown status NCT00365105 Phase 3
41 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3
42 Comparison of Two Radiation Therapy Regimens in Treating Patients With Stage II or Stage III Prostate Cancer Completed NCT00062309 Phase 3
43 Computer-Based Survey and Communication Aid in Improving Physician-Patient Communication and Treatment Decision Making in Patients With Metastatic Cancer Completed NCT00244868 Phase 3
44 Educational Intervention With or Without Telephone Counseling in Increasing Colorectal Cancer Screening Compliance in Brothers and Sisters of Patients With Colorectal Cancer Completed NCT00352638 Phase 3
45 Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer Completed NCT00003313 Phase 3
46 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3
47 The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction Completed NCT00143507 Phase 3
48 Study of APD421 as PONV Treatment (Prior Prophylaxis) Completed NCT02646566 Phase 3
49 Goserelin, Flutamine, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer Completed NCT00767286 Phase 3
50 S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer Completed NCT00004011 Phase 3

Search NIH Clinical Center for Fox-Fordyce Disease

Cochrane evidence based reviews: fox-fordyce disease

Genetic Tests for Fox-Fordyce Disease

Anatomical Context for Fox-Fordyce Disease

MalaCards organs/tissues related to Fox-Fordyce Disease:

39
Skin, Breast

Publications for Fox-Fordyce Disease

Articles related to Fox-Fordyce Disease:

(show top 50) (show all 78)
id Title Authors Year
1
In vivo features of Fox-Fordyce disease in high-definition optical coherence tomography. ( 26713641 )
2016
2
In vivo features of Fox-Fordyce disease in high-definition optical coherence tomography. ( 26972218 )
2016
3
Fox-Fordyce disease of the vulva. ( 27190415 )
2016
4
A female case of Fox-Fordyce disease. ( 27226051 )
2016
5
Fox-Fordyce Disease. ( 26909204 )
2016
6
Effective treatment of Fox-Fordyce disease with pulsed dye laser. ( 27623097 )
2016
7
Fox-Fordyce Disease: An under-diagnosed adverse event of laser hair removal? ( 27135989 )
2016
8
A novel modality using microwave technology for the treatment of Fox-Fordyce disease (FFD). ( 27051811 )
2016
9
Successful treatment of areolar Fox-Fordyce disease with surgical excision and 1550-nm fractionated erbium glass laser. ( 27072751 )
2016
10
Successful treatmeant of refractory pruritic Fox-Fordyce disease with botulinum Toxin Type A. ( 26385128 )
2015
11
Axillary syringomas mimicking Fox-Fordyce disease. ( 26500884 )
2015
12
Clinical Effects of Topical Tacrolimus on Fox-Fordyce Disease. ( 26171257 )
2015
13
Lesions in the axilla after hair removal using intense pulsed light. Fox-Fordyce disease. ( 24838226 )
2015
14
Fox-Fordyce disease: a report of 2 cases responding to topical clindamycin. ( 25566917 )
2015
15
Fox-Fordyce disease with an atypical clinical presentation. ( 23260875 )
2013
16
Fox Fordyce disease as a secondary effect of laser hair removal. ( 24131099 )
2013
17
Fox-Fordyce disease treatment with fractional CO2 laser. ( 24261728 )
2013
18
Clinical effects of topical pimecrolimus in a patient with Fox-Fordyce disease. ( 22571582 )
2012
19
Histopathology attributes of Fox-Fordyce disease. ( 23067079 )
2012
20
Anti-human milk fat globulin staining of perifollicular xanthomatosis inA Fox-Fordyce disease. ( 23181442 )
2012
21
Fox-Fordyce disease. ( 23286818 )
2012
22
Fox-Fordyce disease: response to adapalene 0.1%. ( 22570049 )
2012
23
Fox-Fordyce Disease (Apocrine Miliaria). ( 21751451 )
2011
24
Fox-Fordyce disease following axillary laser hair removal. ( 21576577 )
2011
25
Fox-Fordyce disease in monozygotic female twins. ( 21679831 )
2011
26
Fox-Fordyce disease exacerbated by hyperhidrosis. ( 20537067 )
2010
27
Clinicopathological study of Fox-Fordyce disease. ( 19712275 )
2009
28
Dilation of apocrine glands. A forgotten but helpful histopathological clue to the diagnosis of axillary Fox-Fordyce disease. ( 19461248 )
2009
29
Fox-Fordyce disease in daughter and father. ( 19060475 )
2009
30
Perifollicular xanthomatosis as the hallmark of axillary Fox-Fordyce disease: an evaluation of histopathologic features of 7 cases. ( 18711075 )
2008
31
Pruritic axillary papules. Fox-Fordyce disease. ( 18619083 )
2008
32
Pimecrolimus is effective in Fox-Fordyce disease. ( 16961542 )
2006
33
Fox fordyce disease in a prepubertal girl. ( 15660912 )
2005
34
Axillary perifollicular xanthomatosis resembling Fox-Fordyce disease. ( 15527440 )
2004
35
Patterns histopathologic of Fox-Fordyce disease. ( 15618931 )
2004
36
Axillary perifollicular xanthomatosis resembling Fox-Fordyce disease. ( 15068468 )
2004
37
Fox-Fordyce disease. ( 12705772 )
2003
38
Apoeccrine sweat duct obstruction as a cause for Fox-Fordyce disease. ( 12637930 )
2003
39
Fox-Fordyce disease. ( 12041809 )
2002
40
Axillary Fox-Fordyce disease treated with liposuction-assisted curettage. ( 11939804 )
2002
41
Fox-Fordyce disease: diagnosis with transverse histologic sections. ( 10607326 )
2000
42
Fox-Fordyce disease: two cases in patients with Turner syndrome. ( 10086869 )
1999
43
Fox-Fordyce disease in two prepubertal girls: histopathologic demonstration of eccrine sweat gland involvement. ( 8844748 )
1996
44
Fox-Fordyce disease treated with topical clindamycin solution. ( 7574824 )
1995
45
Fox-Fordyce disease in a male patient--response to oral retinoid treatment. ( 8313643 )
1994
46
Fox-Fordyce disease: successful treatment with topical clindamycin in alcoholic propylene glycol solution. ( 1498406 )
1992
47
Fox-Fordyce disease. Control with tretinoin cream. ( 507892 )
1979
48
Tretinoin treatment for Fox-Fordyce disease. ( 507877 )
1979
49
Fox-Fordyce disease. Self-assessment mini-program. ( 457328 )
1979
50
Hormonal levels in Fox-Fordyce disease. ( 1252362 )
1976

Variations for Fox-Fordyce Disease

Expression for Fox-Fordyce Disease

Search GEO for disease gene expression data for Fox-Fordyce Disease.

Pathways for Fox-Fordyce Disease

Pathways related to Fox-Fordyce Disease according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.87 CD68 CEACAM5 KIT

GO Terms for Fox-Fordyce Disease

Sources for Fox-Fordyce Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....